This study is not yet accepting patients
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Summary
- Eligibility
- for people ages 40-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Harold Chapman, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Harold Chapman, MD
I have had a longstanding interest and productive history in the field of tissue remodeling, particularly as it relates to lung disease and have been continuously RO1 funded since 1991. I have also had virtually two research lives. For many years my work primarily focused on proteolytic enzymes.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hal Chapman
- ID
- NCT05195918
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 50 study participants
- Last Updated